Usage patterns of over-the-counter phenazopyridine (pyridium)

Journal of General Internal Medicine

Volumn 18, Issue 4, 2003, Pages 281-287

  Shi, Chih Wen ^a,e   Asch, Steven M ^c,d   Fielder, Eve ^a   Gelberg, Lillian ^a   Brook, Robert H ^a,c   Leake, Barbara ^a   Shapiro, Martin F ^a   Dowling, Patrick ^a   Nichol, Michael B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Over the counter; Pharmacy; Phenazopyridine; Survey

Indexed keywords

NON PRESCRIPTION DRUG; PHENAZOPYRIDINE;

ADULT; ARTICLE; DRUG MARKETING; DRUG MISUSE; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS MEDIUM; PHARMACY; QUESTIONNAIRE; URINARY TRACT INFECTION;

ADULT; ANESTHETICS, LOCAL; ATTITUDE TO HEALTH; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; LOGISTIC MODELS; LOS ANGELES; MALE; ODDS RATIO; PHENAZOPYRIDINE; QUESTIONNAIRES; SELF MEDICATION; SOCIOECONOMIC FACTORS;

EID: 0038298727     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.2003.20709.x     Document Type: Article

References (42)

1. Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med. 2001;345:810-6.
2. Jacob LR. Prescription to over-the-counter drug reclassification. Am Fam Physician. 1998;57:2209-14.
3. Snyder K. Marketing consumer trends driving switch-hitters up: prescription drugs changing to over-the-counter status. Drug Topics. 1997;89:141.
4. Synder K. Rising tide-New wave of Rx-to-OTC switches coming. Drug Topics. 1995;207:47-9.
5. Rosenau PV. Rx to OTC switch movement. Med Care Rev. 1994;51:429-66.
6. Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss products. JAMA. 2001;286:930-5.
7. Newton G, Popovich NG, Pray WS. Rx-to-OTC switches: from prescription to self-care. J Am Pharm Assoc. 1996;402-20.
8. Karig AW, O'Brien ST, Weintraub M. Look what's going OTC. Patient Care. 1995;29:76-89.
9. Salmo R. Rx to OTC switches curb health care costs. Pharm Times. 1993;59:34-37.
10. Bradley C, Blenkinsopp A. Over-the-counter drugs: the future for self-medication. BMJ. 1996;312:835-7.
11. Kranz H. Over-the-counter drugs: the issues. Drug Saf. 1990;5:120-5.
12. Taylor CA, Lipsky MS. Physician's perceptions of the impact of the reclassification of vaginal antifungal agents. J Fam Pract. 1994;38:157-60.
13. Madhavan S. Schondelmeyer SW. Pharmacists's evaluations of the nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin. Am J Hosp Pharm. 1989;46:2486-92.
14. Gurwitz JH, McLaughlin TJ, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Health Serv Res. 1995;30:672-85.
15. Glossel EA. Implications of the reclassification of drugs from prescription-only to over-the-counter status. Clin Ther. 1991;13:200-15.
16. Lessing M. The OTC drug phenomenon: double-edged clinical implications. Mil Med. 1987;152:557-9.
17. Temin P. Costs and benefits in switching drugs from Rx-to-OTC. J Health Econ. 1983;2:187-205.
18. Feldman M. Pros and Cons of OTC availability of histamine 2-receptor antagonist. Archive Intern Med. Commentary. 1993;153:2415-24.
19. Lipsky MS, Waters T. The "prescription-to-OTC switch" movement: its effects on antifungal vaginitis preparations. Arch Fam Med. 1999;8:297-300.
20. Economic Benefits of Self-Medication. Washington. DC: Kline and Co., Inc.: 1997.
21. Tasch RF, Goeree R, Henke CJ, O'Brien BJ. Switching the histamine 2-receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation. Pharmacoeconomics. 1996;9:61-75.
22. Kalish SC, Bohn RL, Avorn J. Policy analysis of the conversion of histamine2-receptor antagonists to over-the-counter use. Med Care. 1997;35:32-48.
23. Andrade SE, Gurwitz JH, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Med Care. 1999;37(4):424-30.
24. Simons M, Peltz JF. Nonprescription status urged for three allergy drugs. The Los Angeles Times. May 12, 2001. Sect. Nations. Also available at: http://www.latimes.com/news/la-000039884ju1010.story. Accessed March 1, 2002.
25. Bristol-Myers Squibb. OTC rationale for Pravachol. Presentation to the FDA Nonprescription Drugs Advisory Committee. July 14, 2000. Rockville. Md.: FDA Dockets, 2000. Transcripts.
26. Rheinstein PH. Criteria used by the FDA to determine what classes of drugs are suitable switch candidates. Drug Inf J. 1985;19:139-42.
27. Botstein P. Criteria for switching new molecular entities from prescription to over-the-counter. Drug Inf J. 1990;24:29-31.
28. Sihvo S, Hemminki E. Self-medication of dyspepsia: how appropriate is it? Scand J Gastroenterol. 1997;32:855-61.
29. Sihvo S, Ahonen R, Mikander H, Hemminki E. Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns. Fam Pract. 2000;17:145-9.
30. Sihvo S, Hemminki E. Self-medication and health habits in the management of upper gastrointestional symptoms. Patient Educ Couns. 1999;37:55-63.
31. Shaw JP, Ferry DG, Pethica D, Brenner D, Tucker IG. Usage patterns of transdermal nicotine when purchased as a nonprescription medicine from pharmacies. Tob Control. 1998;7:161-7.
32. Stuart B, Grana J. Ability to pay and the decision to medicate. Med Care. 1998;36:202-11.
33. th Ed. New Jersey: Medical Economics; 2000:3164.
34. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993;329:1328-34.
35. rd ed. Baltimore, Md: William and Wilkins; 1991.
36. Litwin M, Shi C, Asch S, Gelberg L, Shapiro M, Brook R. Expert panel meeting, University of California-Los Angeles. Los Angeles. Calif. July 14, 2000.
37. Hunter MS, Liao KL. Intentions to use hormone replacement therapy in a community sample of 45-year-old women. Maturitas. 1994;20:13-23.
38. Myers RE, Ross E, Jepson D, et al. Modeling adherence to colorectal cancer screening. Prev Med. 1994;23:142-51.
39. Aday LA, Andersen R. A framework for the study of access to medical care. Health Serv Res. 1974;9:208-20.
40. Fleming GV, Giachellow MA, Andersen R, Andrade P. Self care: substitute, supplement, or stimulus for formal medical care services? Med Care. 1984;22:950-66.
41. Afifi AA, Clark V. Computer-Aided Multivariate Analysis. New York: Van Norstrand Reinhold Company; 1990.
42. Sommers, SD. Chaiyakunapruk, N. Gardner, JS. Winkler, J. The emergency contraception collaborative prescribing experience in Washington State. J Am Pharm Assoc. 2001;41:60-6.